Tag Archives: Limb-Girdle Muscular Dystrophy Type 2I/R9

AskBio Initiates Clinical Trial for Gene Therapy Targeting Limb-Girdle Muscular Dystrophy Type 2I/R9

(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release